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Abstract—Medical devices like the Implantable Cardioverter
Defibrillator (ICD) are life-critical systems. Malfunctions of the
device can cause serious injury or death of the patient. In addition
to rigorous testing and verification during the development
process, new medical devices often go through clinical trials to
evaluate their safety and performance on sample populations.
Clinical trials are costly and prone to failure if not planned and
executed properly. Evaluating devices on computer models of the
relevant physiological systems can provide helpful insights into
the safety and efficacy of the device, thus helping to plan and
execute a clinical trial. In this paper, we demonstrate how to de-
velop high-level physiological models of cardiac electrophysiology
and how to apply them to the Rhythm ID Head to Head Trial
(RIGHT), a 5-year long clinical trial for comparing two ICDs.
We refer to this as a Computer-Aided Clinical Trial (CACT).
We explored two modeling options, a white-box model capturing
the mechanisms of the physiological behaviors, and a black-
box model which uses machine learning methods to synthesize
physiological input signals. Both models were able to generate
physiological inputs to the ICDs and we discuss the challenges
and appropriateness of the two modeling options.
I. INTRODUCTION
Medical devices have been developed to save and improve
people’s lives. In the U.S. for example, 10,000 people re-
ceive an Implantable Cardioverter Defibrillator (ICD), a heart
rhythm adjustment device, every month [1]. The diagnostic
and therapeutic functions of medical devices are becoming
more autonomous in order to deliver timely therapy and
reduce human labor and error. This increasingly sophisticated
functionality is fulfilled by increasingly complex software.
Both the software and hardware of a medical device are prone
to errors and faults, and the failure modes depend as much on
the design as on the patient’s lifestyle and unique physiology.
Malfunctions of the medical device can cause serious injury or
death of the patient, so these life-critical devices are subject to
much greater regulatory scrutiny and liability than consumer
electronics hardware and software.
The clinical trial is a major difference between the develop-
ment processes of consumer electronics and high-risk medical
devices. In a typical trial, a group of patients that are treated
with the new device are compared to a group of patients who
are treated with the current standard of care (e.g., a different
device currently on the market). The objective is to see whether
the different devices result in significantly different effects
on the patients. Consumer electronics might undergo some
amount of field testing (e.g. a phone company may hand out
prototypes of its latest phone to employees and monitor them),
but it is insignificant compared to a clinical trial1.
A. Device Verification
Verification activities take up most of the time in a typical
hardware (HW) and software (SW) development process (up to
70% for HW by some estimates). Each verification activity has
a sign-off criterion in the Test Plan, indicating that the design
can proceed to the next phase of the development cycle. Such
criteria will usually include successful linting and sufficiently
high coverage metrics (code, functional, data and assertion
coverage in particular). Model checking of certain sub-systems
is also performed, where the sub-systems are chosen based on
their criticality and their size. Finally, integration testing is
performed when the chip is assembled together.
These activities are aimed at verifying that the design obeys
its specification, and the input sequences fed to it during
testing are aimed at that goal. In particular, there is no codified
attempt at replicating the statistics or characteristics of ‘real-
world’ scenarios (at least, not for functionality verification).
In fact, the notion of ‘real-world’ scenarios already assumes a
certain level of abstraction, typically that of a virtual prototype
that can execute the software stack, and most verification
activities listed above happen at the RT level or somewhat
higher.
For medical devices, the real-world scenario is provided by
the real world: the new ICD, say, is implanted in the trial
population, and its efficacy is evaluated at the end of the
trial, while its safety is evaluated throughout the trial. While
a medical device’s HW and SW can undergo the above verifi-
cation activities, their functionality is not considered verified
until they have passed the clinical trial. That’s because, (in
addition to the safety considerations), the human physiology
1Here we ignore post-market data collection since a trial happens before
the new device can be brought to market
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Fig. 1. The separation between medical device development and field test phrase
is so varied that debugging-oriented testing cannot possibly
be comprehensive enough, or give statistically meaningful
estimates of device efficacy.
In this paper we present the argument for Computer-Aided
Clinical Trials (CACTs): a process in which high-level models
of the human physiology are used to evaluate device perfor-
mance on virtual trial populations, and the results of which
are used to help plan a real clinical trial. In Section II we
explain why randomized testing and data sets are insufficient
in a CACT, and why physiology models are needed. We also
discuss the appropriate abstraction level for models in a CACT.
In Section III we give an overview of RIGHT, a 5-year long
trial that compared two ICDs, and for which we conducted a
Computer-Aided Clinical Trial retrospectively to validate our
approach. Sections IV and V present the white-box and black-
box models we built for use in the CACT, and in Section
VI we discuss the implications of using such models for the
verification activities above.
II. THE NEED FOR INPUT MODELS
Why are models of the device’s input needed for CACTs?
Some life-critical devices like ICDs store the input signals
they measure during an arrhythmia episode. Device companies
likely have access to this (anonymized) physiological data.
Isn’t it then possible and sufficient to replay these input signals
to the Design Under Test (DUT), thus foregoing the need for
a model?
The need for physiological input models can be attributed
to three reasons. We will illustrate these reasons using our
running example of an ICD whose input is a 3D real-valued
time series, known as the electrogram, or EGM.
Taming input complexity. The space of physiological input
signals is complicated and with no evident structure. Formally,
the input space is uncountably infinite since the physiological
signal is real-valued, unlike the input to, say, a network router
which contains discrete values. Moreover, the structure of
the input space is far from obvious, unlike a network packet
which has a well-defined, human-engineered structure. In fact,
for a medical device, it is not even clear what is a valid
input and what is not: given a signal, and given the immense
variability of physiologies, how to tell automatically whether
it could’ve been produced by a human heart or not? Modeling
is essential to get a good handle on these aspects and tame
the complexity of the input space. By modeling, we obtain a
finite representation of the input space, impose a structure on
it, and obtain a test of what is a physiologically valid signal
(one that can be produced by the model) and what is not.
Separation of design and validation. Medical device
companies likely have access to a vast set of data that is
retrieved from their devices. This data might then be used
to develop and test the device. Because a CACT is meant
to be an independent assessment of the devices performance,
the data used to develop it cannot be re-used in a CACT. A
CACT that re-uses the development data will likely show very
good performance and bias our estimate of true performance.
Moreover, the data stored by the device might not be in a
format that can be re-played on the DUT. For example, an
ICD only stores arrhythmia episodes. On their own, these do
not constitute a complete input signal to test the ICD.
Paucity of data. Physiological data is not readily available.
By physiological data we mean the signals that are measured
by a medical device and which it uses to diagnose the state of
the patient and apply appropriate therapy. What data is avail-
able is usually siloed in proprietary platforms. Even regional
medical centers don’t have ready access to that data. E.g.,
the arrhythmia episodes that are recorded by an ICD can be
viewed and printed, but not necessarily downloaded in digital
form. Moreover, this data must be manually examined and
labeled by a physician before it can be used to test a device.
This provides a very strong motivation for the development of
simulation models that can generate labeled input signals to
the device.
A. Level of abstraction of the input
It is well-established that the higher the level of the abstrac-
tion, the easier it is to design system inputs and the easier
it is to interpret test results. In HW validation, high-level
modeling (and associated high-level testing) refers variably to
design descriptions in SystemC or SystemVerilog, architectural
descriptions in C/C++, or higher level virtual prototypes that
can execute software meant to run on the HW under test.
The highest possible level of input to a MD is the patient’s
physiological state. However, the latter is not rigorously de-
fined in the way that the state of an SoC is. When evaluating
the power performance of an SoC, the SoC state is either ON,
DROWSY, IDLE, OFF, etc, and each register is initialized to
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Fig. 2. ICD. Reported rates of inappropriate therapy are on a per-
episode basis, as reported in RIGHT
a known value. What is the relevant state of a patient? For an
ICD, the state obviously includes the presence of scars in the
heart’s muscle, history of arrhythmia, age and gender. Should
we include the specific scar pattern? What about economic
status, a failing kidney and a history of smoking? Moreover,
each of these state variables is itself hard to capture. Obtaining
a map of scar tissue in the heart requires an MRI scan, and
the history of arrhythmia is qualitative at best. To turn this
information into an operational input to the device, a lot of
work has yet to happen both on the level of fundamental
science and the level of data mining science.
The second abstraction level, one lower than patient state,
is the description of physiological signals measured by the
device. For an ICD, these are the electrograms. Inputs at a
lower level than that don’t make sense for medical device SW
validation, and are extremely hard to interpret at best. This is
the level at which we build our models of device inputs.
III. CASE STUDY: CLINICAL EVALUATION OF VT/SVT
DISCRIMINATION IN ICDS
Before describing the models we built, we give a quick
overview of ICD functionality and RIGHT. An ICD is an
implantable device designed to treat ventricular arrhythmia,
a life-threatening condition due to irregular electrical activity
of the heart. A dual chamber ICD has two leads inserted into
the heart against the wall of right atrium and right ventri-
cle, respectively (Fig. 2). The leads measure local electrical
activations of the heart which are referred to as electrogram
(EGM) signals. Based on the EGM signals, the ICD diagnoses
the heart condition and delivers therapy during ventricular
tachycardia in the form of electrical pacing or shock to restore
the normal heart rhythm.
Due to limited observability, the ICD algorithm may
not have enough information to discriminate between life-
threatening ventricular tachycardia (VT) and non-fatal supra-
ventricular tachycardia (SVT). Diagnosing an SVT as VT
leads to inappropriate shocks. Inappropriate therapy increases
patient stress and is linked to increased morbidity. Depending
on the particular ICD and its settings, the rates of inappropriate
therapy can reach 62% of all delivered therapy episodes [2]!
A. RhythmID Goes Head-to-head Trial (RIGHT)
ICD manufacturers have developed algorithms to distinguish
VT from SVT in order to reduce the chance for inappropriate
therapy during SVT. The key constraint is that the ICD
must always deliver therapy during a potentially fatal VT. To
evaluate the performance of the algorithms, various clinical
trials have been conducted. One particular trial was conducted
to compare RhythmID, a VT/SVT discrimination algorithm
developed by Boston Scientific, and PRLogic, an algorithm
developed by Medtronic, in terms of time to first inappropriate
therapy. The trial is named RhythmID Goes Head-to-head Trial
(RIGHT). The initial assumption of the trial is that Rhythm ID
is 25% better. The trial enrolled approximately 2000 patients
and lasted 5 years from 2006 to 2011. However, at the end of
the trial, it turned out that PRLogic is 27% better [2], resulting
in trial failure.
Assume we are in 2006 during the planning of the trial. Can
we use computer models of the heart’s electrophysiology to
conduct a Computer-Aided Clinical Trial (CACT) and provide
useful insight that can prevent the trial failure, or lead to a re-
planning of the trial?
B. Requirements for Physiological Models for Computer-
Aided RIGHT
Physiological models generate input signals to a device.
Therefore, they should be specifically developed for the device
they will be connected to, and for the CACT they are meant
to be used in. This poses a different set of restrictions on
the input model than that imposed by the debugging activities
listed above.
• For RIGHT, the objective is to determine whether an
algorithm can make the right VT vs SVT decision: the
model will feed signals to the device, but the device will
not feed signals back to the model. Thus an open-loop
model is appropriate.
• The algorithm should be evaluated on a virtual popu-
lation that shares certain key characteristics with real
populations. Thus there is no need for full input space
coverage, since ‘corners’ of the input space might be rare
conditions.2
• The signals generated by the model need to be physio-
logically plausible, so we can make statistical inferences
based on them. Evaluating device performance on a set of
inputs half of which could not possibly be generated by
a human heart is meaningless. Therefore, the generated
signal set must conform to the statistics of available real
data sets.
• Finally, at the CACT stage, model interpretability is not
as important as during design verification, since the goal
is no longer to re-play bugs and figure out their cause.
Fig. 3 illustrates the importance of these different aspects
in CA RIGHT, compared with device V&V.
2There may be interest in observing the rare conditions, but the point is
that this isn’t strictly needed for the CACT.
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Fig. 3. Importance for different aspects
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Given that a high-level model is essential for generating the
devices input signals, we now ask: what kind of model should
we develop?
IV. WHITE BOX MODELS OF ELECTROPHYSIOLOGY
A white-box model captures the mechanisms for generating
input behaviors. In the context of ICD operation, electrical
depolarizations initiate from various locations of the heart,
and conduct through the electrical conduction system of the
heart. When the heart tissue where ICD leads are implanted
is depolarized, the electrical voltage changes are monitored
by the ICD leads. The resulting waveforms are referred to as
electrogram, or EGM, signals, and constitute the input signals
to the ICD. A white box model for EGM signals should
capture the mechanisms that influence features of the EGM
signals, which in turn affect device behaviors.
One of the challenges for developing white-box models
is the level of abstraction used for modeling. What is the
minimum amount of detail required to distinguish features of
the EGM signals that affect device behaviors? In case of a
dual chamber ICD, the features are the timing and morphology
of the EGM signals, which are determined by the generation
and conduction of electrical depolarizations within the heart.
We developed a white-box heart model for EGM generation,
which is based on the principles of clinical electrophysiology.
As shown in Fig. 4, each solid circle represents a specific
anatomical location of the heart. In this case, we only model
the anatomical locations that can affect the electrical behaviors
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Fig. 5. EGM generation. The timing model produces the events
boolean signal (top left) and the base EGM signatures are overlaid
on the events (bottom left) to produce the final signal (bottom right).
Different arrhythmias are modeled by different timing models (top
right).
between the atrial lead and the ventricular lead of the ICD. For
each location, a state machine models the timing behaviors of
the generation and blocking of electrical depolarizations. The
solid lines in Fig. 4 represent the electrical connections among
anatomical locations of the heart. For each solid line, a state
machine models the timing delay between two locations. We
also model different source of abnormal electrical depolariza-
tions and their connections with the main model structure,
which are represented as dotted circles and lines in Fig. 4.
This model structure generates the timing of electrical
depolarizations for both atrial and ventricular channels. Ac-
cording to the source of the electrical depolarizations, an
EGM morphology is overlayed on top of the timing events,
which completes EGM generation. The EGM morphologies
are collected from EGM signals of real patients. The EGM
generation process is demonstrated in Fig. 5.
For each heart condition, we obtained physiological ranges
for the timing parameters from the clinical literature [3], and
built a synthetic cohort by uniformly sampling from the ranges.
We were able to construct 600 synthetic heart models for
each of 19 heart conditions, and simulated the heart models
to obtain 11,000+ arrhythmia episodes. The EGMs are then
fed into our implementations of RhythmID and PRLogic
algorithms to evaluate their rates of inappropriate therapy.
A. CACT Result With White-box Models
We implemented the two discrimination algorithms based
on the available literature.
1) Rate of Inappropriate Therapy Across Various Popu-
lations: The obtained rates of inappropriate detection were
6.65% for Rhythm ID and 2.91% for PRL+W (P < 0.0001)
on a per-episode basis, assuming an equal number of patients
from each arrhythmia in the synthetic cohort. The corre-
sponding relative improvement of PRL+W over Rhythm ID
is 56%. In other words, the in-silico trial reveals that PRL+W
algorithm differentiates between VT and SVT better than
RhythmID. Our findings are consistent with the observations
of the RIGHT trial itself [2]. We also varied the distribution of
the arrhythmias in the synthetic cohort, and re-computed the
cohort-wide rates of inappropriate therapy. As an example,
Fig. 6 shows the results for the uniform distribution and
a distribution that approximates that of RIGHT’s cohort [2,
Table 1]. It can be seen that indeed, PRL+W maintains a better
rate of arrhythmia discrimination across the board.
2) Effect of Device Parameter Setting: In HW verification,
different versions of the same HW are tested. E.g., a single
core, dual core, and quad core versions of a processor may
be tested. Or, different memory sizes’ impact on latency and
power consumption may be evaluated. Each version is targeted
towards a different market segment.
Analogously, ICDs have a number of parameters which
can be tuned by the physicians to accommodate specific
patient conditions. One of the main causes of VT/SVT mis-
classifications is inappropriate parameter setting [4]. For the
physicians to set appropriate parameters, it is very important
to understand how the change of one parameter can affect the
discriminating capability of the algorithm. With CACT, one
can subject the same synthetic population to different settings
of the parameters at virtually no cost. This is impossible to
do with a real trial, since a patient cannot be implanted with
two devices. In the CA RIGHT we evaluated the effect of
two ICD parameters on specificity and sensitivity of PRL+W.
The first parameter is the duration of arrhythmia before the
ICD makes a therapy decision. The parameter for PRL+W
is the number of consecutive fast ventricular intervals which
can be set from 8 to 20 beats. In this experiment we explore
the values {8,10,12,16,18,24,30} . From the results (Fig. 7)
we observe that the specificity increases monotonically with
the length of the duration, which matches the intuition as the
device can examine a longer history of the arrhythmia episode
6.65
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Uniform Distribution
RIGHT Distribution
Rate of inappropriate Therapies
Rate of inappropriate Therapies
Fig. 6. Rate of inappropriate detection (2nd column) for different
arrhythmia distributions (1st column). The upper-left distribution is
uniform, and the lower-left distribution is that of the baseline charac-
terization in RIGHT [2]. The x-axis lists the simulated arrhythmias.
Fig. 7. Effect of Duration and VF threshold params on Specificity
with longer duration, and also allows a greater chance for the
arrhythmia to self-terminate. This can prevent inappropriate
detections therefore prevent inappropriate therapies.
The second parameter we varied is the VF threshold. If the
ventricular rate is faster than the VF threshold for a period
of time the ICD will confirm detection and deliver therapy
without going into the SVT/VT discrimination algorithm.
In this experiment we explored the values {170,184,200}
msec. As the value increases, specificity also increases as
more episodes are examined by the SVT/VT discrimination
algorithm.
The result of of changing the two parameters matches the
clinical results in [5] which further confirms the usefulness of
CACT.
B. Discussion
The advantage of white-box modeling in the current context
is two-fold: first, by construction, it provides the sequence of
events, in the heart, that led to the generation of a particular
signal. In our example, the model shows how electrical signals
conduct throughout the heart, which can distinguish VT from
SVT. Second, by changing parameters that have a physio-
logical meaning, white-box models enable the simulation of
clinically relevant rare scenarios.
However, white-box models have a major disadvantage,
which is the inability to identify joint distributions of the
model’s parameters from patient data. Our EGM-generating
white box model has over 30 timing parameters. Ranges for
individual timing parameters can be found in the clinical liter-
ature [3]. However, the joint distribution of these parameters
is not available. Identifying them during a clinical procedure
is theoretically possible, but practically impossible. Not being
able to identify the joint distribution of the parameters dimin-
ishes model validity and its capability to represent specific
patient groups. Both of these aspects are important for CACT.
Moreover, white-box modeling also requires a significant
amount of domain-specific and device-specific knowledge to
construct.
These disadvantages do not prevent the use of white-box
modeling during device evaluation. For example, the diabetes
model developed in University of Virginia is a white-box
model. FDA accept simulation results of the model as a
substitute for animal trials, which saves significant time and
money, and reduces animal testing.
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V. BLACK BOX MODELS OF ELECTROPHYSIOLOGY
In contrast to a white box model, a black box model
does not seek to model the mechanisms that generate the
physiological signals. Rather, it directly models the emergent
phenomenon that is the physiological signals. In the context
of ICD verification, for example, the input to the ICD consists
of a 3-dimensional time series yt ∈ <3, t ∈ {t1, . . . , tm},
called the electrogram. See Fig. 8. Following [6], such a time
series can be modeled as being generated by a Hidden Markov
Model (HMM). An HMM is a finite state machine whose
transitions are probabilistic: the probability of transitioning
between states xi and xj is given by Aij , 1 ≤ i, j ≤ N .
Matrix A is the transition probability matrix. In our case, the
time series is modeled as being generated by the repetition of
a finite number of motifs sk, k = 1, . . . ,K. Each motif is a
short duration signal sk : [0, Tk] → <3. See Fig. 8 (b). The
repetitions of a motif are not identical: two parameters, φ and
ρ, enable time-varying modifications, as follows. A state of
the HMM is given by x = (k, ρ, φ). At each time step t, if the
current state of the HMM is xt = (kt, ρt, φt), then the model
produces the value yt = φt · skt(ρt) + νt, where sk is the kth
motif, φt is the scaling factor, ρt ∈ [0, Tk] is the time of a
motif sample, and νt is a stochastic noise value. By sampling
different values of k along the time series, different motifs are
used (and repeated). With each repetition, the values φ and ρ
serve to slightly alter the appearance of the motif.
The motifs sk and transition matrix A are learned from
data using Expectation-Maximization (EM), a classical soft
clustering algorithm. The data used for learning is a set of
electrograms, each of which is labeled by the arrhythmia
and patient that produced it. This data is much more readily
available than the data needed to fit timing parameters to
the white-box model. Briefly, EM has two steps: in the
Expectation (E) step, a matrix A and set of motifs sk are
given, and we infer the most likely sequence of HMM states
x = (xt)t≤N that explains the time series y = (yt)t≤N : x =
argmaxxP (y | x). In the Maximization (M) step, x is used
to update the motifs and the matrix A. The E and M steps are
iterated until convergence. EM is usually implemented using
Viterbi decoding for the E step, and various descent algorithms
for the M step. See [7] for an excellent introduction to HMMs
and EM. Fig.
Thus, for a given patient, and for a given arrhythmia, we can
learn a black-box generative model. This model is then used
to produce more exemplars of that arrhythmia, while obeying
key statistical characteristics of real patient data. To generate a
synthetic electrogram, we simply transition through the learned
HMM using the transition probability matrix A. At time t, the
state xt is used to produce yt in the manner described above.
Just like the white box model, the generated electrograms are
used as input to the device under test. A black box model is
attractive because it can be learned from available data, thus
automatically providing a measure of validity (i.e. confidence
that when we simulate it, it will produce physiologically valid
signals). It can also be simulated in real-time or faster, thus
allowing for fast testing. And under suitable restrictions, if an
appropriate device model is available, it could even be model
checked.
One disadvantage of a black box model is its weak in-
terpretability. The HMM bears no relation to physiological
mechanisms such as ionic channels, muscle contractions, or
wave propagation. The parameters of the model dont neces-
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Fig. 9. Ability to perform tasks with either type of model. More
stars indicates it is easier to perform that task. Thus it is easier to do
closed-loop testing with a white box model than it is with a black
box model.
sarily have any physiological meaning. E.g. the conduction
delay parameters of the automaton model of Section IV can
be traced to the physiology of the heart generating the signal.
In the HMM model on the other hand, the parameters include
the state transition probability matrix A, which does not have
a clear physiological interpretation. Thus if the CACT reveals
poor device performance, we usually cant correlate that to any
underlying physiological state of the patient, since this aspect
is not part of the model (except to the degree that we know
something about the population on whose data the model was
trained to begin with). The doctors, on the other hand, are most
interested in the patients physiological state (see discussion in
Section II-A), and use the electrograms as a proxy for that. The
lack of physiological interpretation also prevents the black-
box model to be used in any closed-loop CACTs in which the
physiological model is required to respond to device output.
VI. DISCUSSION
In the last two sections, we discussed the two modeling
options that we explored for a Computer-Aided RIGHT (CA
RIGHT). Fig. 9 compares the ability of both models to capture
the aspects discussed in Fig. 3. From the comparison we can
see that the black-box model is more suitable for CA RIGHT
while the white-box model is more suitable to perform closed-
loop V & V. It is essential to determine the most suitable
model during the planning of a CACT to minimize the effort
of model revisions.
Generally, developing physiological models for a CACT
includes answering the following questions:
1) Is the CACT a closed-loop trial or an open-loop trial?
2) If the CACT is open-loop, what are the characteristics
of the input signals?
3) If the CACT is closed-loop, what are the physiological
mechanisms that affect the input signals and respond to
device outputs?
4) What is the minimum model that can capture the char-
acteristics and/or the physiological mechanisms?
5) How valid is the model?
6) Is there patient data available with enough quality and
quantity to identify the parameters of the physiological
model?
Once a model has been developed and used to run a CACT
for the DUT, can’t it also be used to test the next generation
of the device? Indeed it can (though this implies that it cannot
be used in any future CACTs - see Separation of design and
validation in Section II above). Using physiological models
as we described them does pose some unique challenges when
measuring medical device performance, and we briefly outline
some of these in this section.
SW (and HW) sign-off is usually dependent on several
coverage metrics exceeding pre-set levels. For example, code
coverage needs to be above, say, 90%. Some of these metrics,
like code coverage, are relatively removed from the abstraction
level of the high-level physiological inputs (e.g, electrograms).
If code coverage is too low, it may not be obvious what new
input signals would increase it. Inputs to a medical device are
more similar to a video stream used to test a video processing
application than to a test sequence to some HW.
A probabilistic black box model does not readily allow the
generation of corner cases, since the model will, by definition,
generate signals from the (learned) distribution. If the bug-
revealing corner case is in the distribution support, it will take
a long time to produce.3 And if it is not in the distribution
support, it can never be produced. While HW randomized
testing allows us to vary the distribution from which the input
transactions are generated, a learned black box model does not
provide as much freedom. That’s because the distribution is
learned from data and changing it might reduce the validity of
the generated signals. Therefore, if, say, functional coverage
of the device is too low, we need another model altogether
to generate the directed tests that finally get us above the
coverage threshold required for sign-off.
Using a probabilistic model also complicates model check-
ing, since the model checker must now return probabilistic
answers. Probabilistic model checkers do exist for certain
types of models like Discrete-Time Markov Chains [8], and it
remains to be seen whether they scale to the input models we
are interested in.
VII. CONCLUSION
The testing and validation of life-critical medical devices
requires the conducting of a clinical trial. These trials are
lengthy and costly, and the idea of using computer models
of the physiology to help plan and execute the trial is very
attractive. Physiological modeling happens at a very high
level, and has unique challenges that distinguish it from other
modeling efforts aimed at device debugging. In particular,
the need for physiological validity, which has no counterpart
in testing of consumer electronics, requires learning model
parameters from real patient data. While these models can be
re-used for device testing, several challenges complicate their
direct usage to achieve the usual sing-off criteria of coverage.
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